Mateusz Kaczmarek

A technology and finance expert writing for TS2.tech. He analyzes developments in satellites, telecommunications, and artificial intelligence, with a focus on their impact on global markets. Author of industry reports and market commentary, often cited in tech and business media. Passionate about innovation and the digital economy.

Coca-Cola (KO) Stock Rockets on Board Shake-Up and Bold Moves – What Investors Need to Know

Coca-Cola (KO) Stock Rockets on Board Shake-Up and Bold Moves – What Investors Need to Know

Sources: Recent Reuters and MarketBeat analyses, and The Coca-Cola Company’s own filings and press releases (cited above), provide the data and quotes used herein reuters.com reuters.com investors.coca-colacompany.com reuters.com ts2.tech. The market data reflect trading as of Oct. 17, 2025.
Intuitive Surgical Stock Primed for Rally on FDA Approvals and Congressional Buying

Intuitive Surgical Stock Primed for Rally on FDA Approvals and Congressional Buying

Stock Performance & Analyst Consensus Intuitive’s stock has been volatile in 2025. It gained ground last week on optimism (e.g. up ~2.7% on Oct. 17) and now sits around $446 investing.com marketbeat.com. Over the past year, the price swung between about $425 and $616 investing.com. At ~$446, ISRG trades at a high single-digit P/E (~60x) compared to the medtech sector, but analysts argue much of Intuitive’s growth is already priced in. Institutional sentiment is upbeat: 22 of 32 surveyed analysts rate ISRG a Buy, with an average 12-month target of roughly $576 investing.com (implying ~29% upside). For example, RBC Capital
CRISPR Therapeutics Stock Explodes on Gene-Editing Breakthroughs – Analysts See 35% Upside

CRISPR Therapeutics Stock Explodes on Gene-Editing Breakthroughs – Analysts See 35% Upside

Clinical and Pipeline Progress CRISPR Therapeutics has reported a string of positive R&D updates in recent weeks. On October 10, 2025, CRSP presented preclinical results for CTX460, its SyNTase-based therapy for alpha-1 antitrypsin deficiency (AATD). The data – highlighted at the ESGCT conference – showed that a single dose of CTX460 delivered by lipid nanoparticles corrected the disease-causing mutation in >90% of liver cells and boosted functional AAT protein ~5-fold in animal models globenewswire.com. “The preclinical results demonstrate the potential of CTX460, developed using our novel SyNTase editing platform, to correct the mutation with precision and efficiency,” said CRISPR CMO
Chevron (CVX) Stock: Oil Price Doldrums, Pipeline Deal & Analysts’ Forecasts – What’s Next?

Chevron (CVX) Stock: Oil Price Doldrums, Pipeline Deal & Analysts’ Forecasts – What’s Next?

Current Stock Performance Chevron’s stock (NYSE: CVX) has been relatively flat in recent days. After closing around $152–153 last week investing.com, CVX closed at $153.08 on Oct 17 (up ~0.9% that day) investing.com. This puts it roughly in the middle of its 5-day range ($150–154) investing.com. Year-to-date CVX has lagged some competitors, reflecting weaker oil prices and the cost of merging Hess. For context, the broad S&P 500 is near all-time highs, while energy stocks are under pressure. Still, technical indicators (e.g. moving averages) suggest Chevron is holding important support in the mid-$140s. Recent Price Moves: Oil markets have swung
Boeing Stock Surges: FAA Clears Production Boost and Big Orders Fuel Rally

Boeing Stock Surges: FAA Clears Production Boost and Big Orders Fuel Rally

FAA Approves Higher Output In a major positive for Boeing, the FAA on Oct 17 announced it had “conducted extensive reviews” and would allow Boeing to ramp 737 MAX output to 42 per month reuters.com. Boeing immediately confirmed it would “begin boosting production quickly” reuters.com. Boeing CEO Kelly Ortberg had long said the company was “pretty confident” it could raise the rate to 42 by year-end reuters.com, and after regulatory approval he outlined plans for subsequent increases in five-jet increments reuters.com. Tech investor site TechStock² noted the FAA news alongside other positives: “U.S. regulators cleared Boeing to boost 737 MAX output
18 October 2025
Starbucks (SBUX) Brewing Gains? CEO’s Shake-Up & $5B China Deal Fuel Stock Rally

Starbucks (SBUX) Brewing Gains? CEO’s Shake-Up & $5B China Deal Fuel Stock Rally

Starbucks stock trades in the mid-$80s (Nasdaq: SBUX) after a recent bounce; it remains down about 9–10% over the past year ts2.tech simplywall.st. CEO Brian Niccol has launched a $1 billion “Back to Starbucks” turnaround – closing roughly 1% of U.S./Canada stores (several hundred locations) and cutting ~900 corporate jobs ts2.tech reuters.com. Q3 FY2025 results (ended July) were weak: EPS $0.50 (missing consensus) and profit plunged ~47% YOY on higher costs ts2.tech marketbeat.com. Wall Street is cautiously optimistic: ~⅔ of analysts rate SBUX a Buy, with an average 12‑month target around $100–105 (roughly 17–20% above current prices) ts2.tech stockanalysis.com. Labor tensions
Ford (F) Stock Plunges After Supplier Fire and EV Slump — Can It Rebound?

Ford (F) Stock Plunges After Supplier Fire and EV Slump — Can It Rebound?

Stock Performance and Recent Moves Ford’s stock has been on a roller-coaster. After trading near 52-week highs around $12 in late summer, shares tanked in early Oct. on several setbacks. TechStock² reports that F shares closed “around $11.92 on Friday, October 17, 2025” ts2.tech, recovering modestly after an initial drop. The slide was triggered by a supplier plant fire, sending shares down ~6–7% in a day ts2.tech, and more recently by large recalls. (By comparison, Ford’s stock is still up roughly 25% YTD due to strong truck sales earlier in the year ts2.tech.) Trading volume has been high; as of
18 October 2025
Exxon Mobil (XOM) Stock on Rollercoaster Ride – Oil Crashes & Big News Spark Wild Market Debate

Exxon Mobil (XOM) Stock on Rollercoaster Ride – Oil Crashes & Big News Spark Wild Market Debate

Recent Stock Performance Exxon Mobil’s stock has been relatively steady in mid-October. After closing at about $112.24 on Oct. 17 stockanalysis.com, the shares are near their 50-day and 200-day moving averages (~$111 marketbeat.com). That recent price places XOM roughly flat for October and slightly up year-to-date (~+6.5% YTD, vs down ~3% over 12 months simplywall.st). (A Simply Wall St analysis noted XOM closed around $114.26 on Oct 8, up 4.6% that month simplywall.st.) After a late-summer rally in oil, crude prices plunged again: WTI dipped under $59 recently (a five-month low) ts2.tech, prompting energy stocks to lag. In the week of Oct 4–5,
18 October 2025
GRAIL (GRAL) Stock Skyrockets on Samsung’s $110M Bet and Cancer-Screening Breakthrough

GRAIL (GRAL) Stock Skyrockets on Samsung’s $110M Bet and Cancer-Screening Breakthrough

GRAIL’s logo at company headquarters. The Menlo Park biotech specializes in blood-based early cancer screening through its Galleri test news.samsung.com tradingview.com. GRAIL, Inc. is focused on early cancer detection – its mission is “to detect cancer early when it can be cured” news.samsung.com. The company’s Galleri test analyzes tumor DNA in blood to screen for dozens of cancers in asymptomatic adults. Recently, two developments have driven the stock: Samsung’s strategic deal (announced Oct. 16) and positive trial data (released at ESMO). These moves suggest GRAIL is gaining traction, but they also highlight the challenges ahead in turning cutting-edge science into
Disney Stock Could Soar? Analysts Pin 20% Upside on Streaming Shake-Up and Park Growth

Disney Stock Could Soar? Analysts Pin 20% Upside on Streaming Shake-Up and Park Growth

Steady Stock Performance, Mixed Trends Disney’s share price has been relatively flat in 2025 after rallying in 2024. As of Oct. 17 the stock sat around $110.7 marketbeat.com, roughly unchanged from early January. Over the last few days DIS has traded in a narrow $109–112 range stockanalysis.com. Year-to-date Disney is up only ~0.8% benzinga.com, underperforming the broader market rally. In late September and early October the stock dipped into the high-$100s, but analysts say any pullback may present a buying opportunity given Disney’s upcoming catalysts. Trading volumes have been healthy, with recent sessions showing average daily volume (~10–15 million shares).
Apple Stock Could Explode After New AI Chip Launch and iPhone 17 “Supercycle,” Analysts Say

Apple Stock Could Explode After New AI Chip Launch and iPhone 17 “Supercycle,” Analysts Say

Apple’s stock is trading near record levels as of mid-October 2025. Last week (Oct. 13–17), AAPL shares oscillated in the $247–$252 range, closing at $252.29 on Oct. 17 historicalstockprice.com. That is only a few dollars below the all-time intraday high (~$260) set in late September ts2.tech historicalstockprice.com. Technically, AAPL is above both its 50-day and 200-day moving averages ts2.tech, signaling positive momentum. However, the stock’s 2025 performance has been muted: it is up only about 1–2% on the year ts2.tech. This flatness contrasts sharply with many other mega-cap tech stocks: for example, Nvidia is +35% YTD, Microsoft +23%, and Alphabet +29% ts2.tech.
18 October 2025
GE Aerospace Stock Rockets as Rally Continues – Q3 Earnings, Contracts, and Analyst Targets in Focus

GE Aerospace Stock Rockets as Rally Continues – Q3 Earnings, Contracts, and Analyst Targets in Focus

Surging Stock Performance GE Aerospace (NYSE: GE) shares have been on a tear in 2025, roughly doubling from lows. As of Oct 17, 2025, the stock closed around $300 reuters.com. That’s up about 78% this year intelligentinvestor.com.au – one of the best performances among mega-cap industrials. The 52-week high is $307.25 and the low was $159.36 reuters.com, reflecting a remarkable rebound as the company emerged as a pure-play aerospace engine maker. (Before April 2024, GE had spun off its energy and healthcare units, leaving “GE Aerospace” as its primary business under ticker GE.) Trading volumes have been healthy (typically >1M
18 October 2025
1 60 61 62 63 64 171
Go toTop